{"title": "PPT - Tema 24. Hepatitis S\u00e9ricas PowerPoint Presentation, free download - ID:5686637", "author": "Marina", "url": "https://www.slideserve.com/marina/tema-24-hepatitis-s-ricas", "hostname": "slideserve.com", "description": "Tema 24. Hepatitis S\u00e9ricas. Clasificaci\u00f3n. Hepatitis de transmisi\u00f3n parenteral. Virus de la hepatitis B, D, C y G. Caracter\u00edsticas generales Estructura Ciclo de multiplicaci\u00f3n viral. Patogenia. Inmunidad. Cuadros cl\u00ednicos. Diagn\u00f3stico. Tratamiento. Epidemiolog\u00eda y Profilaxis.", "sitename": "SlideServe", "date": "2014-10-21", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "380 likes | 952 Views\nTema 24. Hepatitis S\u00e9ricas. Clasificaci\u00f3n. Hepatitis de transmisi\u00f3n parenteral. Virus de la hepatitis B, D, C y G. Caracter\u00edsticas generales Estructura Ciclo de multiplicaci\u00f3n viral. Patogenia. Inmunidad. Cuadros cl\u00ednicos. Diagn\u00f3stico. Tratamiento. Epidemiolog\u00eda y Profilaxis.\nE N D\n[Tema 24. Hepatitis S\u00e9ricas](https://image3.slideserve.com/5686637/slide1-l.jpg) \u2022 Clasificaci\u00f3n. \u2022 Hepatitis de transmisi\u00f3n parenteral. \u2022 Virus de la hepatitis B, D, C y G. \u2022 Caracter\u00edsticas generales \u2022 Estructura \u2022 Ciclo de multiplicaci\u00f3n viral. \u2022 Patogenia. \u2022 Inmunidad. \u2022 Cuadros cl\u00ednicos. \u2022 Diagn\u00f3stico. \u2022 Tratamiento. \u2022 Epidemiolog\u00eda y Profilaxis. [HEPATITIS V\u00cdRICAS: EVOLUCI\u00d3N HIST\u00d3RICA](https://image3.slideserve.com/5686637/slide2-l.jpg) \u2022 Hepatitis A \u2022 Hepatitis B \u2022 Hepatitis no A no B: C, D, E, G, \u2026.? \u2022 Com\u00fan: Afectan al h\u00edgado Ictericia Enzimas hep\u00e1ticas elevadas [VIRUS DE LA HEPATITIS B: CARACTER\u00cdSTICAS](https://image3.slideserve.com/5686637/slide4-l.jpg) \u2022 Virus de ADN parcialmente bicatenario envuelto \u2022 Familia Hepadnaviridae \u2022 Distintos tipos antig\u00e9nicos de comportamiento similar \u2022 No cultivable [VIRUS DE LA HEPATITIS B: ](https://image3.slideserve.com/5686637/slide8-l.jpg) REPLICACI\u00d3N VIRAL [HEPATITIS B: CL\u00cdNICA](https://image3.slideserve.com/5686637/slide11-l.jpg) \u2022 Periodo de incubaci\u00f3n m\u00e1s largo(7-160 d\u00edas) \u2022 Inicio m\u00e1s lento \u2022 Todas las edades \u2022 Afectaci\u00f3n hep\u00e1tica moderada \u2022 Existen casos cr\u00f3nicos: \u2022 Adultos: 10 % \u2022 Neonatos: 90 % [HEPATITIS B: DIAGN\u00d3STICO](https://image3.slideserve.com/5686637/slide13-l.jpg) \u2022 Detecci\u00f3n de la ADN polimerasa \u2022 Detecci\u00f3n ADN viral: hibridaci\u00f3n o PCR \u2022 Detecci\u00f3n de Ags y Acs por t\u00e9cnicas de ELISA: \u2022 Anti-HBc \u2022 HBsAg/Anti-HBs \u2022 HBeAg/Anti-HBe \u2022 \u00a1 Patrones serol\u00f3gicos \u201cimposibles\u201d en infecciones por cepas mutantes ! [HEPATITIS B: EPIDEMIOLOG\u00cdA](https://image3.slideserve.com/5686637/slide16-l.jpg) \u2022 Distribuci\u00f3n mundial (350 millones de infectados cr\u00f3nicamente) \u2022 Endemicidad variable (depende del porcentaje de portadores cr\u00f3nicos asintom\u00e1ticos [0,3-8%]) \u2022 Reservorio: Hombre infectado \u2022 Transmisi\u00f3n: \u2022 Parenteral (0.0001 ml de sangre) \u2022 Sexual \u2022 Vertical o materno-fetal [Geographical Prevalence of Hepatitis B Virus (HBV)](https://image3.slideserve.com/5686637/slide17-l.jpg) Based on 2005 data, WHO. [HEPATITIS B: PROFILAXIS](https://image3.slideserve.com/5686637/slide18-l.jpg) \u2022 Vacuna \u2022 Medidas de \u00edndole general \u2022 Control de donaciones de sangre, hemo-derivados y \u00f3rganos \u2022 Uso de material desechable \u2022 M\u00e9todos de barrera \u2022 Inmunizaci\u00f3n pasiva [Recombinant HBV Vaccine Production](https://image3.slideserve.com/5686637/slide19-l.jpg) The steps involved in preparing a recombinant DNA hepatitis B vaccine in yeast. [VIRUS DE LA HEPATITIS D (DELTA)](https://image3.slideserve.com/5686637/slide20-l.jpg) \u2022 Virus de ARN monocatenario peque\u00f1o y defectivo (necesita al Ag HBs para infectar y replicarse) \u2022 15 millones de infectados en el mundo \u2022 40% de hepatitis fulminantes [VIRUS DE LA HEPATITIS D (DELTA)](https://image3.slideserve.com/5686637/slide21-l.jpg) \u2022 Formas de presentaci\u00f3n: \u2022 Coinfecci\u00f3n VHB + VHD: aumenta la gravedad de VHB \u2022 Sobreinfecci\u00f3n en pacientes con HB cr\u00f3nica: progresi\u00f3n m\u00e1s r\u00e1pida y grave \u2022 Diagn\u00f3stico serol\u00f3gico (Ig espec\u00edficas) \u2022 Epidemiolog\u00eda y profilaxis las de la HB [VIRUS DE LA HEPATITIS C](https://image3.slideserve.com/5686637/slide22-l.jpg) \u2022 Virus de ARN de polaridad positiva, se multiplica mediante una retro-transcriptasa \u2022 Familia Flaviviridae \u2022 No cultivable \u2022 Diferentes genotipos con distinto compor-tamiento \u2022 La infecci\u00f3n suele ser asintom\u00e1tica o leve \u00a1\u00a1\u00a1\u00a1 \u2022 Hasta el 85% de los casos cronifican [Geographical Prevalence of Hepatitis C Virus (HCV)](https://image3.slideserve.com/5686637/slide23-l.jpg) Based on 2003 data, WHO. [POR QU\u00c9 EL VHC TIENDE A LA CRONICIDAD](https://image3.slideserve.com/5686637/slide27-l.jpg) \u2022 El virus tiene frecuentes errores en la replicaci\u00f3n \u2192 frecuente aparici\u00f3n de mutantes \u2022 La respuesta inmune resulta ineficaz frente a los mutantes \u2022 El virus se asocia a la c\u00e9lula e inhibe la apoptosis \u2022 Reacci\u00f3n inmuno-patol\u00f3gica [VIRUS DE LA HEPATITIS C](https://image3.slideserve.com/5686637/slide28-l.jpg) \u2022 Diagn\u00f3stico: \u2022 Dif\u00edcil en formas agudas \u2022 Serolog\u00eda en formas cr\u00f3nicas (???) \u2022 Detecci\u00f3n de ARN viral \u2022 Transmisi\u00f3n: Parenteral (menos importantes las v\u00edas sexual, salvo si se padece otra ETS, y vertical, salvo en coinfectadas por VIH) \u2022 Profilaxis: \u2022 Control de transfusiones y transplantes \u2022 No hay vacunas [VIRUS DE LA HEPATITIS G](https://image3.slideserve.com/5686637/slide29-l.jpg) \u2022 Virus de ARN de polaridad positiva. Familia Flaviridae \u2022 Frecuente coinfecci\u00f3n con VHC y VHB \u2022 Prevalencia: \u2022 Donantes: 0,3-2% \u2022 Drogadictos: 3-10% \u2022 Africanos: 8-20% \u2022 Transmisi\u00f3n parenteral \u2022 Diagn\u00f3stico: detecci\u00f3n de ARN viral o Ac espec\u00edficos \u2022 No hay vacunas [Riesgo de contraer virus de transmisi\u00f3n parenteral tras](https://image3.slideserve.com/5686637/riesgo-de-contraer-virus-de-transmisi-n-parenteral-tras-exposici-n-ocupacional-l.jpg) exposici\u00f3n ocupacional \u2022 Seg\u00fan la OMS, como consecuencia de 3.000.000 accidentes anuales el personal sanitario se han infectado: \u2022 1.000 por VIH \u2022 66.000 por hepatitis B. \u2022 16.000 por hepatitis C.", "language": null, "image": "https://cdn3.slideserve.com/5686637/slide1-n.jpg", "pagetype": "article", "links": ["\\", "#", "/presentations", "/presentations", "/topics", "/updates", "/featured", "/powerpoint-templates", "/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/article-stories", "/online-survey", "/online-quiz", "/lead-generation", "/create?type=ebook&utm_source=slideserve&utm_medium=website&utm_campaign=ebook+creator", "https://www.slideserve.com/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/pro", "/upload", "/marina", "https://image3.slideserve.com/5686637/slide1-l.jpg", "https://image3.slideserve.com/5686637/slide2-l.jpg", "https://image3.slideserve.com/5686637/slide3-l.jpg", "https://image3.slideserve.com/5686637/slide4-l.jpg", "https://image3.slideserve.com/5686637/slide5-l.jpg", "https://image3.slideserve.com/5686637/slide6-l.jpg", "https://image3.slideserve.com/5686637/slide7-l.jpg", "https://image3.slideserve.com/5686637/slide8-l.jpg", "https://image3.slideserve.com/5686637/slide9-l.jpg", "https://image3.slideserve.com/5686637/slide10-l.jpg", "https://image3.slideserve.com/5686637/slide11-l.jpg", "https://image3.slideserve.com/5686637/slide12-l.jpg", "https://image3.slideserve.com/5686637/slide13-l.jpg", "https://image3.slideserve.com/5686637/slide14-l.jpg", "https://image3.slideserve.com/5686637/slide15-l.jpg", "https://image3.slideserve.com/5686637/slide16-l.jpg", "https://image3.slideserve.com/5686637/slide17-l.jpg", "https://image3.slideserve.com/5686637/slide18-l.jpg", "https://image3.slideserve.com/5686637/slide19-l.jpg", "https://image3.slideserve.com/5686637/slide20-l.jpg", "https://image3.slideserve.com/5686637/slide21-l.jpg", "https://image3.slideserve.com/5686637/slide22-l.jpg", "https://image3.slideserve.com/5686637/slide23-l.jpg", "https://image3.slideserve.com/5686637/slide24-l.jpg", "https://image3.slideserve.com/5686637/slide25-l.jpg", "https://image3.slideserve.com/5686637/slide26-l.jpg", "https://image3.slideserve.com/5686637/slide27-l.jpg", "https://image3.slideserve.com/5686637/slide28-l.jpg", "https://image3.slideserve.com/5686637/slide29-l.jpg", "https://image3.slideserve.com/5686637/riesgo-de-contraer-virus-de-transmisi-n-parenteral-tras-exposici-n-ocupacional-l.jpg", "https://image3.slideserve.com/5686637/slide31-l.jpg", "https://image3.slideserve.com/5686637/slide32-l.jpg", "/Roberta/viral-hepatitis-prevention", "/PamelaLan/the-alphabet-of-hepatitis-101", "/virote/epidemiologic-update-hepatitis-c", "/overton/today-we-will", "/albert/hepatitis-cr-nica-y-hepatitis-cr-nica-por-vhb", "/saxon/hepatitis-b-and-hepatitis-b-vaccine", "/bernad/lecture-29-hepatitis-viruses-deborah-taylor-ph-d", "/zelia/viral-hepatitis", "/chavez/inflammaton-of-the-liver-hepatitis-d-c-e-viruses-part", "/kapila/hepatitis", "/sandro/hepatitis-a", "/kelton/hepatitis-c", "/geneva/acute-viral-hepatitis", "/denzel/hepatitis-b-and-hepatitis-b-vaccine", "/vilmos/hepatitis-a-e-viruses-powerpoint-ppt-presentation", "/creola/diagnose-van-hepatitis-b-en-hepatitis-c", "/elsie/25-hepatitis-virus", "/mieko/viral-hepatitis-powerpoint-ppt-presentation", "/emele/hepatitis-c", "/joy-short/the-alphabet-of-hepatitis", "/russell-odom/hepatitis-c", "/chelsea-mayer/hepatitis", "//www.slideserve.com", "//fr.slideserve.com", "/about", "/privacy", "/dmca", "https://blog.slideserve.com", "/contact", "https://www.facebook.com/SlideServe", "https://twitter.com/slideserve", "https://www.youtube.com/user/SlideServe", "https://www.pinterest.com/slideserve/"]}